Clinuvel Pharmaceuticals

Update in progress

CUV.AX (ASX)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Clinuvel Pharmaceuticals is an Australian biopharmaceutical company focused on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening disorders. Its lead drug, SCENESSE, protects adults with erythropoietic protoporphyria from phototoxicity. The pipeline includes CUV9900, PRÉNUMBRA, and NEURACTHEL, plus melanocortin technology and photocosmetic products. Founded in 1999, it is based in Melbourne.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive